|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.90 USD | -0.44% |
|
-8.13% | +16.96% |
| Market Cap | 2.64B 2.32B 2.16B 1.98B 3.72B 254B 3.78B 25.62B 10.01B 125B 9.92B 9.7B 432B | P/E 2026 * |
-6.01x | P/E 2027 * | -37.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.21B 1.94B 1.8B 1.65B 3.11B 213B 3.16B 21.41B 8.36B 104B 8.29B 8.11B 361B | EV / Sales 2026 * |
2.95x | EV / Sales 2027 * | 2.21x |
| Free-Float |
96.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | -0.44% | ||
| 1 week | -8.13% | ||
| Current month | -19.44% | ||
| 1 month | -12.58% | ||
| 3 months | +11.62% | ||
| 6 months | +10.65% | ||
| Current year | +16.96% |
| 1 week | 26.5 |  | 29.1 |
| 1 month | 26.5 | | 36.57 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Matthew Fust
BRD | Director/Board Member | 61 | 2013-12-31 |
Michael Narachi
BRD | Director/Board Member | 66 | 2015-02-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/1/26 | Sell | Chief Financial Officer | -4,698 | 0.0048% | ||
| 6/15/26 | Sell | Director | -2,000 | 0.0020% | ||
| 6/15/26 | Sell | General Counsel | -1,899 | 0.0019% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.44% | -8.13% | -1.61% | -36.17% | 2.64B | |
| -1.26% | -8.94% | +31.43% | -84.94% | 1.66B | |
| 0.00% | -2.77% | -13.28% | -15.68% | 317M | |
| 0.00% | +1.05% | -51.12% | - | 52.45M | |
| Average | -0.42% | -3.24% | -8.65% | -45.60% | 1.17B | |
| Weighted average by Cap. | -0.70% | -7.72% | +8.77% | -52.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 748M 657M 611M 561M 1.05B 72.06B 1.07B 7.26B 2.84B 35.43B 2.81B 2.75B 122B | 991M 870M 809M 743M 1.4B 95.43B 1.42B 9.61B 3.76B 46.92B 3.72B 3.64B 162B |
| Net income | -469M -412M -383M -352M -661M -45.18B -671M -4.55B -1.78B -22.21B -1.76B -1.72B -76.79B | -81.69M -71.75M -66.72M -61.23M -115M -7.87B -117M -792M -310M -3.87B -307M -300M -13.37B |
| Net Debt | -434M -381M -355M -325M -611M -41.81B -621M -4.21B -1.65B -20.56B -1.63B -1.59B -71.07B | -447M -393M -366M -335M -630M -43.09B -640M -4.34B -1.7B -21.19B -1.68B -1.64B -73.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-24 | US$26.90 | -0.44% | 1,495,624 |
| 26-07-23 | US$27.02 | -2.26% | 1,888,467 |
| 26-07-22 | US$27.65 | -3.41% | 1,546,510 |
| 26-07-21 | US$28.62 | +0.32% | 2,275,867 |
| 26-07-20 | US$28.53 | -2.56% | 1,255,077 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Select your edition
All financial news and data tailored to specific country editions
